help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deppe, C. E.
Right arrow Articles by Lombès, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deppe, C. E.
Right arrow Articles by Lombès, M.
Endocrinology Vol. 143, No. 5 1932-1941
Copyright © 2002 by The Endocrine Society


RENIN-MINERALOCORTICOIDS-ANF-ADH

Cyclosporine A and FK506 Inhibit Transcriptional Activity of the Human Mineralocorticoid Receptor: A Cell-Based Model to Investigate Partial Aldosterone Resistance in Kidney Transplantation

Christine E. Deppe1, Peter J. Heering, Say Viengchareun, Bernd Grabensee, Nicolette Farman and Marc Lombès

INSERM, U-478, IFR02, Faculté de Médecine Xavier Bichat (C.E.D., S.V., N.F., M.L.), 75870 Paris, France; and Klinik für Nephrologie und Rheumatologie, Heinrich Heine Universität (C.E.D., P.J.H., B.G.), 40225 Dusseldorf, Germany

Address all correspondence and requests for reprints to: Dr. Marc Lombès, INSERM, U-478, IFR02, Faculté de Médecine Xavier Bichat, 16 rue Henri Huchard, BP 416, 75870 Paris Cedex 18, France. E-mail: . mlombes{at}bichat.inserm.fr

Abstract

Renal transplant recipients treated with cyclosporine A (CsA) and FK506 (tacrolimus) develop signs of hypoaldosteronism despite normal plasma aldosterone levels, suggesting a relative resistance of the distal nephron to aldosterone action. To examine the effects of immunosuppressants on human MR (hMR) function, we established the M cell model, renal tubular cells stably transfected with hMR. Upon CsA and FK506 administration, hMR mRNA levels and aldosterone binding in M cells remained unchanged (maximum number of sites, ~80 fmol/mg protein; Kd = ~1 nM). Aldosterone-dependent intracellular localization of green fluorescent protein-hMR was not affected by immunosuppressants. A major impact of CsA or FK506 on the multidrug resistance gene product in cellular accumulation of aldosterone was also excluded. In contrast, aldosterone-stimulated hMR transcriptional activity was reduced to 53 ± 11.2% (P < 0.03) after pretreatment of M cells for 3 d with CsA and to 71 ± 9.6% (P < 0.05) after pretreatment with FK506. These effects were both time and concentration dependent (IC50 of CsA, 10-6 M; IC50 of FK506, 10-5 M) and needed at least 2 d to develop. Such an inhibitory effect does not depend on the N-terminal part of hMR, as CsA also reduced transcriptional activity of a 1–453 deletion mutant of hMR. Our results demonstrate that immunosuppressants inhibit hMR transcriptional activity without affecting hMR expression, aldosterone binding properties, and hMR nucleocytoplasmic trafficking. They suggest that ion transport alterations in renal graft recipients are in part induced by impaired hMR function.




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
L.-J. Min, M. Mogi, J. Iwanami, J.-M. Li, A. Sakata, T. Fujita, K. Tsukuda, M. Iwai, and M. Horiuchi
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence
Cardiovasc Res, December 1, 2007; 76(3): 506 - 516.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
Y. Sainte Marie, A. Toulon, R. Paus, E. Maubec, A. Cherfa, M. Grossin, V. Descamps, M. Clemessy, J.-M. Gasc, M. Peuchmaur, et al.
Targeted Skin Overexpression of the Mineralocorticoid Receptor in Mice Causes Epidermal Atrophy, Premature Skin Barrier Formation, Eye Abnormalities, and Alopecia
Am. J. Pathol., September 1, 2007; 171(3): 846 - 860.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Ouvrard-Pascaud, Y. Sainte-Marie, J.-P. Benitah, R. Perrier, C. Soukaseum, A. N. D. Cat, A. Royer, K. Le Quang, F. Charpentier, S. Demolombe, et al.
Conditional Mineralocorticoid Receptor Expression in the Heart Leads to Life-Threatening Arrhythmias
Circulation, June 14, 2005; 111(23): 3025 - 3033.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. Pascual-Le Tallec, F. Simone, S. Viengchareun, G. Meduri, M. J. Thirman, and M. Lombes
The Elongation Factor ELL (Eleven-Nineteen Lysine-Rich Leukemia) Is a Selective Coregulator for Steroid Receptor Functions
Mol. Endocrinol., May 1, 2005; 19(5): 1158 - 1169.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
P. Sartorato, F. Cluzeaud, J. Fagart, S. Viengchareun, M. Lombes, and M.-C. Zennaro
New Naturally Occurring Missense Mutations of the Human Mineralocorticoid Receptor Disclose Important Residues Involved in Dynamic Interactions with Deoxyribonucleic Acid, Intracellular Trafficking, and Ligand Binding
Mol. Endocrinol., September 1, 2004; 18(9): 2151 - 2165.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
R. Higgins, K. Ramaiyan, T. Dasgupta, H. Kanji, S. Fletcher, F. Lam, and H. Kashi
Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities
Nephrol. Dial. Transplant., February 1, 2004; 19(2): 444 - 450.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
L. Pascual-Le Tallec, O. Kirsh, M.-C. Lecomte, S. Viengchareun, M.-C. Zennaro, A. Dejean, and M. Lombes
Protein Inhibitor of Activated Signal Transducer and Activator of Transcription 1 Interacts with the N-Terminal Domain of Mineralocorticoid Receptor and Represses Its Transcriptional Activity: Implication of Small Ubiquitin-Related Modifier 1 Modification
Mol. Endocrinol., December 1, 2003; 17(12): 2529 - 2542.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
T. R. Hubler, W. B. Denny, D. L. Valentine, J. Cheung-Flynn, D. F. Smith, and J. G. Scammell
The FK506-Binding Immunophilin FKBP51 Is Transcriptionally Regulated by Progestin and Attenuates Progestin Responsiveness
Endocrinology, June 1, 2003; 144(6): 2380 - 2387.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society